Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib-Reference-Cited by-同舟云学术

Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib

Published:2004-07 Issue:1 Volume:45 Page:93-104
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Takano Toshimi,Ohe Yuichiro,Kusumoto Masahiko,Tateishi Ukihide,Yamamoto Seiichiro,Nokihara Hiroshi,Yamamoto Noboru,Sekine Ikuo,Kunitoh Hideo,Tamura Tomohide,Kodama Tetsuro,Saijo Nagahiro

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference23 articles.

1. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors;Nakagawa;Ann. Oncol.,2003

2. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial;Ranson;J. Clin. Oncol.,2002

3. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase I trial;Herbst;J. Clin. Oncol.,2002

4. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types;Baselga;J. Clin. Oncol.,2002

5. A multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (The IDEAL 1 Trial);Fukuoka;J. Clin. Oncol.,2003

Cited by 163 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk factors for interstitial lung disease in patients with non-small cell lung cancer with epidermal growth factor receptor-tyrosine kinase inhibitors: A systematic review and meta-analysis;Respiratory Investigation;2024-05

2. Drug-induced interstitial lung disease: a narrative review of a clinical conundrum;Expert Review of Respiratory Medicine;2024-02

3. Successful dabrafenib and trametinib combination therapy in a patient with recurrent BRAF^V600E‐mutant non‐small‐cell lung cancer and coexisting radiation pneumonitis;Respirology Case Reports;2024-01

4. A Case of Osimertinib-Induced Eosinophilic Pneumonia;Clinical Lung Cancer;2022-11

5. Respiratory Complications;Holland‐Frei Cancer Medicine;2022-10-21